Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

An estimated 45,000 people have sued Merck, contending the drug caused heart attacks and strokes. Merck has spent more than $1 billion on legal fees during the last three years on Vioxx cases and has vowed to contest each lawsuit, The New York Times reported Tuesday.

Merck, the third-largest U.S. drug maker, is betting its aggressive resistance will reduce the number of cases and, ultimately, its liability, the Times reported. The result is a legal limbo in which even those who have won a case against Merck have yet to see any money because Merck immediately appeals, the newspaper said.

Estimates of Merck's liability, once as high as $25 billion, now is closer to $5 billion, corporate risk analysts told the Times.

Copyright 2007 by United Press International

Explore further: Japan first nation to approve Novartis psoriasis drug

add to favorites email to friend print save as pdf

Related Stories

Mass. doctor accused of faking pain pill data

Mar 11, 2009

(AP) -- A Massachusetts anesthesiologist has been accused of faking data for a dozen years in 21 published studies that suggested after-surgery benefits from painkillers including Vioxx and Celebrex.

When is a drug too risky to stay on the market?

Jun 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

FDA drug approvals mostly flat in 2009

Jan 05, 2010

(AP) -- Drug approvals from the Food and Drug Administration were flat last year compared with 2008 and warnings fell, even as the agency's new leadership struck a tougher stance on safety.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

Dec 22, 2014

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.